Charles A Powell, MD, MBA
- DIRECTOR, MOUNT SINAI-NATIONAL JEWISH HEALTH RESPIRATORY INSTITUTE
- PROFESSOR | Medicine, Pulmonary, Critical Care and Sleep Medicine
Specialties:
Pulmonary Medicine (Lung), Critical Care MedicineDr. Charles A. Powell is Professor of Medicine and System Division Chief for Pulmonary, Critical Care and Sleep Medicine at the Icahn School of Medicine at Mount Sinai in New York and Medical Director of Respiratory Therapy at Mount Sinai Hospital. He received his medical degree at University of Chicago and trained in Internal Medicine at Columbia University and in Pulmonary and Critical Care Medicine at Boston University. A primary focus of Dr. Powell’s research and clinical activities is lung cancer. He also directs research programs focused on early detection of lung interstitial disease and airways disease. Dr. Powell is NIH funded, has published over 100 articles, and directs a NIH funded laboratory that examines the genomics of lung cancer and lung fibrosis. He was the founding chair of the ATS Assembly on Thoracic Oncology and he sees patients in consultation regarding lung nodules and lung cancer. Dr. Powell’s International Reputation in the field is demonstrated by his election as President of the Fleischner Society. Dr. Powell is the CEO of the Mount Sinai-National Jewish Health Respiratory Institute that is a partnership of The Icahn School of Medicine at Mount Sinai, a top ranked academic medical center in New York City, and National Jewish Health, the nation’s leading respiratory hospital based in Denver, Colorado. Combining the strengths of both entities into an integrated Respiratory Institute brings together leading expertise in diagnosing and treating all forms of respiratory illness and lung disease, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and bronchiectasis. Through the integration of research advances, clinical skill and patient-focused processes and protocols, the Respiratory Institute offers a model for the state-of-the- art delivery of multidisciplinary, outcomes-driven care, and for the application of precision medicine for the treatment of respiratory disease.
https://www.washingtonpost.com/video/national/health-science/how-a-desperate-need-for-ventilators-sparked-innovation--voices-from-the-pandemic/2020/04/29/a413b181-ca34-49ba-aa9f-5a73dda983fa_video.html
https://www.nytimes.com/2020/04/17/health/ventilators-coronavirus.html
https://www.nbcnewyork.com/news/national-international/breast-pumps-sleep-apnea-machines-ventilator-shortage-spurs-innovation/2367415/
https://nypost.com/2020/04/07/manhattan-doctor-puts-elon-musks-apnea-masks-to-use/
https://www.dotmed.com/news/story/50730
https://www.nytimes.com/2020/04/30/well/live/coronavirus-days-5-through-10.html
https://video.foxnews.com/v/6148794516001#sp=show-clips
Dr. Powell is registered to provide telehealth services in Florida.
Videos
Certifications
Critical Care Medicine
Pulmonary Disease
Clinical Focus
- Bronchoscopy, Diagnostic
- COVID-19 Lung Disease
- Lung Cancer
Multi-Disciplinary Training Area
Artificial Intelligence and Emerging Technologies in Medicine [AIET]Education
MD, University of Chicago
Residency, Internal Medicine, Columbia-Presbyterian Medical Center
Fellowship, Pulmonary & Critical Care, Boston University
Lung adenocarcinoma can progress from an indolent in situ carcinoma to an invasive, aggressive, metastatic tumor. The WHO/IASLC/ATS Lung adenocarcinoma classification emphasizes the distinction of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma from their invasive counterparts. Molecular biomarkers of invasion can distinguish invasive from non-invasive tumors, a distinction that is typically difficult to make in small biopsies and cytology specimens and is becoming increasingly important as the recognition of early stage adenocarcinoma increases with the widespread implementation of lung cancer screening programs in the United States. Please visit the Charles Powell Lab.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Powell during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- AstraZeneca; BioClinica Inc.; Bristol-Myers Squibb; Clario; Daiichi-Sankyo Co., Ltd.; Eisai Inc.; IQVIA; Senhwa Biosciences, Inc.; Silverback Therapeutics
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.